Pharmacokinetics of Carboplatin and Etoposide in a Hemodialysis Patient with Small Cell Lung Carcinoma.
スポンサーリンク
概要
- 論文の詳細を見る
The pharmacokinetics of intravenously administrated carboplatin (CBDCA) and etoposide (VP-16) were studied in a patient with small cell lung carcinoma (T1N0M0, Stage I) receiving regular hemodialysis for chronic renal failure. The patient was treated with carboplatin at 300mg/m<SUP>2</SUP> on day 1 and etoposide at 50mg/m<SUP>2</SUP> on day 1 and day 3 via intravenous drip infusion for 1 hour. Hemodialysis was performed 2 hours after the start of administration for 4 hours. The pharmacokinetic results revealed that similar pharmacokinetic curves to those of patients with normal renal function were obtained using this regimen. No severe side effects were observed. These observations suggest that this regimen is a safe and useful chemotherapy regimen against malignant disease in patients undergoing regular hemodialysis.
- 特定非営利活動法人 日本肺癌学会の論文
特定非営利活動法人 日本肺癌学会 | 論文
- 診療科からみた新しいTNM病期分類（UICC-7）の問題点と課題?画像診断からみた問題点と課題?
- 新潟県における肺がんの解析
- 慢性血栓塞栓性肺高血圧症合併肺腺癌に対する左上葉切除術を施行した1例
- 肺がん検診における判定基準の改訂（2）：B，C，D判定に関して
- 片側性多発脳神経障害（Garcin症候群）を契機に発見され，化学療法により神経症状の改善を得た小細胞肺癌の1例